Innovative Supported
Otheraddition of connected tools and stronger accompaniment to improve quality of life
NCT Number: NCT03457623
The goal of this study is to evaluate the health and social benefit of innovative management - IsereADOM - versus conventional follow-up in patients with heart failure.
There is a medico-economic goal too, is to perform a cost-utility analysis of the service bundle (IsereADOM) versus conventional 6-month community-based follow-up in a population with heart failure.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
CHU Grenoble-Alpes, Grenoble, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
addition of connected tools and stronger accompaniment to improve quality of life
Time frame: 6 months
The outcome measure is the number of hospitalization
University Hospital, Grenoble
Other
Medico-economic Evaluation of a "IsereADOM" Package of Services Versus Conventional Health and Social Monitoring, in the Care of a Population of People With Heart Failure in Isère.
Acronym: CardIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05750953
Cardiovascular Diseases, Colon Rectal Cancer
Stavanger, Rogaland, Norway
View Trial DetailsNCT02061319
Cardiovascular Diseases, Heart Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT06576050
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT04113109
Cardiovascular Diseases, Heart Diseases
Nashville, Tennessee, United States
View Trial Details